【03/26更新】(株)リプロセル【4978】に注目が集まっているようです。これからどうなる！？掲示板の反応まとめ。

ＩＲ待つか

会社は月曜朝までにIR出す義務があるな
社会に希望持たせる義務がある

噂は本当だった
なら
月曜から１０００向かうな

『COVID-19 Coverage
EpiVax continues to drive science forward with several COVID-19 vaccine program efforts. Please follow our coverage here for updates on vaccine development, both local and global, as well as media coverage and important public health information.


UPDATE March 25, 2020:
Why epitope vaccines?
Immune responses to viral infections can sometimes be detrimental to the host. While some viral antibodies are beneficial (anti-viral), others can actually be virus-aiding. They allow the virus access to cells through non-traditional pathways such as the Fc-receptor. This is called antibody dependent enhancement (ADE).
EpiVax is developing, among many others, an epitope-focused vaccine against CoV-SARS-2. These novel vaccine candidates focus the immune response on specifically creating T cell memory to CoV-SARS-2. This strategy likely minimizes the B cell and antibody response compared to whole antigen/whole pathogen vaccine formulations, thereby significantly reducing the risks associated with ADE.
Read more about EpiVax’s approach on epitope vaccine design here.
UPDATE March 24, 2020:
Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations
EpiVax announces it’s involvement in an international consortium for the rapid development of a mRNA vaccine for high risk populations, which include health care workers and families of those with confirmed cases.
The partnership formed between EpiVax, aTheRNA, Nexelis, REPROCELL and CEV will utilize three technologies:
eTheRNA’s proprietary Trimix technology: an mRNA-based vaccine adjuvant that stimulates dendritic cells into activating a strong CD4 and CD8 T cell response.
A combination of T cell epitopes from the virus brought together on a single mRNA construct. For SARS-CoV-2 this will employ an in-silico epitope prediction and design approach from EpiVax Inc. to identify the target.
An intranasal vaccine delivery platform using a nasal atomizer and a proprietary formulation that delivers the mRNA to the nasal mucosa and optimizes expression. One of the most promising formulation candidates is being repurposed for clinical use in collaboration with REPROCELL.
Read more about the collaboration efforts here
UPDATE March 23, 2020:
With all proposed collaborations in place, EpiVax is poised to make a great impact on the rapid development of a COVID-19 vaccine. However, the vaccine will not come without funding. The Coalition for Epidemic Preparedness Innovations (CEPI) has called for $2 Billion USD in immediate government funding for the expansion of vaccine candidates brought to clinical trial, and the increase in chances of success.
EpiVax is happy to share that a request for funding has been submitted to MCDC (DOD). We are eager to be a part of the solution and look forward to continuing driving science forward.
UPDATE March 20, 2020:
While we continue to pursue multiple vaccine collaborators, one of our top priorities remains health care workers. EpiVax is developing an epitope based vaccine that could be ready in as little as 6 months. Scientists at EpiVax have a plan in place for carrying out this rapid development:
』

ダウ　日経先物　やばいね。

蓄膿症でも大丈夫

そ

Intranasal delivery has been chosen since the mucosa of the upper respiratory tract are the immune system’s primary line of defense. A strong nasal-cell effector and memory response is claimed to fight viral replication, colonization of the lung and thus disease. mRNA has also been demonstrated to induce strong T-cell responses by intranasal delivery.

なぜ買い煽るのか...
みんな損するのに

終わってんなwwwww

終わってんなwwwww

なんか出るの期待してリプロだけにした

リプロ恋！
リプロ恋！
リプロ恋！

リプロセルあほすぎｗｗｗ
何回だまし上げにつられてかってるんや

リプロセルは、iPS細胞作製サービスとか、コロナのワクチンとかのIR期待だろ

リプロセルまえと同じだな
お前らの損切りを好感してから上きてる

リプロセルなに？？

リプロ吹き上がるぞ

リプロセル高値

>>648
１０時に出ない時点ででねーよｗ
昨日のリプロ風説と同じ

>>263
動物実験
人間で治験しているリプロセルの方がまし

リプロセル何で下がってしまったんですか？

リプロこれふざけてんの？

リプロだめじゃん(´･ω･｀)

リプロセルっておぼえてる？

リプロ全モしそうやん

あんだけリプロセル注意喚起したのにPTSから寄りで買ったやつ息しとるんか？

リプロセルS高買い奴状態だな

リプロはまだここか(´・ω・｀)

アンジェスもリプロも似たり寄ったりの材料でイマイチパンチが無いな

リプロの方が速そうじゃねーか

リプロのIR出ないんですけどぉー！！！

リプロはIRでるかなぁ

ただの動物実験なのにｗ
リプロなんか臨床でっせ

リプロセル！！！！

コロナ銘柄に加わったリプロセル、上がります！！